Barclays PLC Acquires 47,059 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Barclays PLC lifted its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 79.6% during the 3rd quarter, Holdings Channel reports. The firm owned 106,174 shares of the company’s stock after purchasing an additional 47,059 shares during the period. Barclays PLC’s holdings in Nautilus Biotechnology were worth $303,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in NAUT. Dimensional Fund Advisors LP increased its holdings in shares of Nautilus Biotechnology by 19.8% during the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock worth $1,345,000 after purchasing an additional 94,908 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Nautilus Biotechnology by 11.2% during the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after purchasing an additional 14,100 shares during the period. SG Americas Securities LLC bought a new position in shares of Nautilus Biotechnology during the third quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Nautilus Biotechnology by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after purchasing an additional 9,404 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Nautilus Biotechnology during the third quarter worth approximately $67,000. 50.71% of the stock is owned by institutional investors.

Nautilus Biotechnology Trading Down 1.2 %

NASDAQ NAUT opened at $1.67 on Monday. The firm has a market capitalization of $209.69 million, a price-to-earnings ratio of -2.98 and a beta of 1.14. The firm’s 50 day simple moving average is $2.19 and its 200 day simple moving average is $2.46. Nautilus Biotechnology, Inc. has a 1 year low of $1.61 and a 1 year high of $3.25.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same quarter last year, the business posted ($0.13) EPS. On average, equities research analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group cut shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.